Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QA108 granules in intermediate AMD
NCT07189169Phase 3Recruiting
- Start
- Jul 2025
- Primary completion
- Mar 2027
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in age-related macular degeneration (AMD) comparing QA108 granules with Placebo (2 arms). Primary endpoint: Percentage change from baseline in drusen area at 24 weeks. Started Jul 2025; status: recruiting.
02
Drugs
QA108
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT07189169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07189169.